Filed: 8/12/2025ACC: 0001104659-25-076820
📋 What this filing means
FORESITE CAPITAL MANAGEMENT V, LLC filed this quarterly 13F‑HR report disclosing 6 equity positions with a total reported market value of $80.73M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
6
Positions
$80.73M
Total AUM (reported)
8.11M
Total Shares
Allocation by class
COM$67.11M83.1%
COM CL A$13.62M16.9%
Portfolio Concentration
Top 3$59.28M73.4%
4–10$21.45M26.6%
Top 3 weight
73.4%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 8.11M
Sole
Full voting authority
8.11M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole6
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings6
Rows:
CG Oncology, Inc.
SOLEShares1M
TypeSH
Market value$26.11M
32.34%
Sole
1M
Shared
0.00
None
0.00
Alumis Inc
SOLEShares5.78M
TypeSH
Market value$17.34M
21.48%
Sole
5.78M
Shared
0.00
None
0.00
Disc Medicine, Inc.
SOLEShares299.07K
TypeSH
Market value$15.84M
19.62%
Sole
299.07K
Shared
0.00
None
0.00
Hims & Hers Health, Inc.
SOLEShares273.15K
TypeSH
Market value$13.62M
16.87%
Sole
273.15K
Shared
0.00
None
0.00
Maze Therapeutics Inc
SOLEShares345.19K
TypeSH
Market value$4.24M
5.25%
Sole
345.19K
Shared
0.00
None
0.00
Lyell Immunopharma Inc
SOLEShares406.65K
TypeSH
Market value$3.59M
4.45%
Sole
406.65K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
CG Oncology, Inc.SOLE | COM | 1M | SH | $26.11M 32.34% | 1M | 0.00 | 0.00 |
Alumis IncSOLE | COM | 5.78M | SH | $17.34M 21.48% | 5.78M | 0.00 | 0.00 |
Disc Medicine, Inc.SOLE | COM | 299.07K | SH | $15.84M 19.62% | 299.07K | 0.00 | 0.00 |
Hims & Hers Health, Inc.SOLE | COM CL A | 273.15K | SH | $13.62M 16.87% | 273.15K | 0.00 | 0.00 |
Maze Therapeutics IncSOLE | COM | 345.19K | SH | $4.24M 5.25% | 345.19K | 0.00 | 0.00 |
Lyell Immunopharma IncSOLE | COM | 406.65K | SH | $3.59M 4.45% | 406.65K | 0.00 | 0.00 |